These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 21540336)
1. Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of duchenne muscular dystrophy. Sazani P; Ness KP; Weller DL; Poage DW; Palyada K; Shrewsbury SB Int J Toxicol; 2011 May; 30(3):313-21. PubMed ID: 21540336 [TBL] [Abstract][Full Text] [Related]
2. Chemical and mechanistic toxicology evaluation of exon skipping phosphorodiamidate morpholino oligomers in mdx mice. Sazani P; Ness KP; Weller DL; Poage D; Nelson K; Shrewsbury AS Int J Toxicol; 2011 May; 30(3):322-33. PubMed ID: 21540335 [TBL] [Abstract][Full Text] [Related]
3. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Cirak S; Arechavala-Gomeza V; Guglieri M; Feng L; Torelli S; Anthony K; Abbs S; Garralda ME; Bourke J; Wells DJ; Dickson G; Wood MJ; Wilton SD; Straub V; Kole R; Shrewsbury SB; Sewry C; Morgan JE; Bushby K; Muntoni F Lancet; 2011 Aug; 378(9791):595-605. PubMed ID: 21784508 [TBL] [Abstract][Full Text] [Related]
4. Toxicological Characterization of Exon Skipping Phosphorodiamidate Morpholino Oligomers (PMOs) in Non-human Primates. Carver MP; Charleston JS; Shanks C; Zhang J; Mense M; Sharma AK; Kaur H; Sazani P J Neuromuscul Dis; 2016 Aug; 3(3):381-393. PubMed ID: 27854228 [TBL] [Abstract][Full Text] [Related]
5. Safety pharmacology and genotoxicity evaluation of AVI-4658. Sazani P; Weller DL; Shrewsbury SB Int J Toxicol; 2010; 29(2):143-56. PubMed ID: 20110565 [TBL] [Abstract][Full Text] [Related]
6. Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice. Negishi Y; Ishii Y; Shiono H; Akiyama S; Sekine S; Kojima T; Mayama S; Kikuchi T; Hamano N; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y Mol Pharm; 2014 Mar; 11(3):1053-61. PubMed ID: 24433046 [TBL] [Abstract][Full Text] [Related]
7. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice. Malerba A; Thorogood FC; Dickson G; Graham IR Hum Gene Ther; 2009 Sep; 20(9):955-65. PubMed ID: 19469709 [TBL] [Abstract][Full Text] [Related]
8. Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys. Webb MS; Tortora N; Cremese M; Kozlowska H; Blaquiere M; Devine DV; Kornbrust DJ Antisense Nucleic Acid Drug Dev; 2001 Jun; 11(3):155-63. PubMed ID: 11446591 [TBL] [Abstract][Full Text] [Related]
9. Prediction of Human Pharmacokinetics of Phosphorodiamidate Morpholino Oligonucleotides in Duchenne Muscular Dystrophy Patients Using Viltolarsen. Imai S; Suda Y; Mori J; Sasaki Y; Yamada T; Kusano K Drug Metab Dispos; 2023 Oct; 51(10):1428-1435. PubMed ID: 37468285 [TBL] [Abstract][Full Text] [Related]
10. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108 [TBL] [Abstract][Full Text] [Related]
11. Duchenne muscular dystrophy drugs face tough path to approval. Hodgkinson L; Sorbera L; Graul AI Drugs Today (Barc); 2016 Mar; 52(3):199-202. PubMed ID: 27186594 [TBL] [Abstract][Full Text] [Related]
12. Golodirsen: First Approval. Heo YA Drugs; 2020 Feb; 80(3):329-333. PubMed ID: 32026421 [TBL] [Abstract][Full Text] [Related]
18. Systemic administration of PRO051 in Duchenne's muscular dystrophy. Goemans NM; Tulinius M; van den Akker JT; Burm BE; Ekhart PF; Heuvelmans N; Holling T; Janson AA; Platenburg GJ; Sipkens JA; Sitsen JM; Aartsma-Rus A; van Ommen GJ; Buyse G; Darin N; Verschuuren JJ; Campion GV; de Kimpe SJ; van Deutekom JC N Engl J Med; 2011 Apr; 364(16):1513-22. PubMed ID: 21428760 [TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold? Guncay A; Yokota T Future Med Chem; 2015; 7(13):1631-5. PubMed ID: 26423833 [No Abstract] [Full Text] [Related]
20. Antisense drug discovery and development. Yamamoto T; Nakatani M; Narukawa K; Obika S Future Med Chem; 2011 Mar; 3(3):339-65. PubMed ID: 21446846 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]